{
    "clinical_study": {
        "@rank": "136169", 
        "acronym": "CURIEFOCALE", 
        "arm_group": {
            "arm_group_label": "Focal brachytherapy", 
            "arm_group_type": "Experimental", 
            "description": "Focal brachytherapy with permanent I125 localized implant."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot prospective biomedical study of interventional type which includes 17\n      patients on 24 months (12 months of inclusion and 12 months of follow-up).\n\n      The objective of this study is to verify that the focal therapy technique used (with the\n      help of Koelis\u00ae system) allows to obtain optimal dosimetric coverage of the prostate target\n      (ie dose of 160 Gy +-5% delivered on the envelope isodose) evaluated by CT scan performed 30\n      days after implantation."
        }, 
        "brief_title": "Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Localized Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men of more than 18 years old\n\n          2. Patient with localized prostate cancer with a good prognosis (AMICO classification),\n             ie satisfying the following conditions according to the urologist medical record\n             transmitted:\n\n               -  Lesion classified T1c or T2a based on digital rectal exam\n\n               -  histologically proven diagnosis of prostatic adenocarcinoma with a Gleason score\n                  \u2264 6\n\n               -  Serum Prostatic Specific Antigen (PSA) <10ng/ml\n\n          3. Patient for whom the Multidisciplinary Consultative Meeting (RCP) has adopted the\n             following treatment options: active surveillance, brachytherapy, radical\n             prostatectomy or external radiation\n\n          4. Patient with good micturating function at inclusion, defined by IPSS score <10 (IPSS\n             Questionnaire)\n\n          5. Patient for whom the result of centralized PSA assay confirms a serum level < 10ng/ml\n\n          6. Patient for whom the unique and intracapsular character of the target area (area to\n             be treated) was confirmed on pre implantation multimodal MRI imaging (ESUR Score \u2265 9)\n             and whose major axis has a size \u2264 20 mm\n\n          7. Patient with a Gleason score on the target \u2264 6 (3 +3) confirmed on biopsies performed\n             using KOELIS \u00ae system and with no other derogatory criteria such as the invasion of\n             the entire core or the presence of a grade 4 or perineural emboli\n\n          8. Patients without history of transurethral resection that could have significantly\n             modified the anatomy of the gland nor obstructive adenoma\n\n          9. Patient who accepts, at the end of the study, the principle of active surveillance\n             for the rest of the gland and the treated area according to the current standard\n             protocol\n\n         10. WHO \u2264 2\n\n         11. Patient with life expectancy > 10 years\n\n         12. Informed consent obtained and signed before any specific procedure in the study\n\n         13. Patient affiliated to social security regimen\n\n        Exclusion Criteria:\n\n          1. Image in favour of the crossing of the capsule, based on pre-implantation multimodal\n             MRI (stage T2 MRI only)\n\n          2. Image in favor of the invasion of the seminal vesicle, based on pre-implantation\n             multimodal MRI (stage T2 MRI only)\n\n          3. Multifocal lesions (ESUR \u2265 9/15) to the pre-implantation multimodal MRI and for which\n             biopsies have shown the cancerous nature\n\n          4. Lesion with larger diameter \u2265 20mm, to the pre-implantation multimodal MRI\n\n          5. Patient who requires pre-implantation hormonal treatment in order to reduce prostatic\n             volume\n\n          6. Patient with current indication against prostate brachytherapy, including a\n             significant limitation of the  mobility of the hips, a prostate volume greater than\n             60 cm3 (measured by planimetry MRI) or a significant dysuria (IPSS \u2265 10)\n\n          7. Patient unable to follow procedures, visits, examinations described in the the study\n\n          8. Patient with absolute indication against imaging tests (significant claustrophobia,\n             wearing a heart valve, pacemaker, ..)\n\n          9. Man of childbearing age who do not want follow the instructions about sexual\n             activities and condom use during the days following the treatment of brachytherapy\n             and / or unwilling to hold (him or her partner) effective contraception for the\n             duration of the study\n\n         10. Any concomitant or previous malignant disease in the past five years with the\n             exception of superficial basal cell carcinoma or non-metastatic of the skin\n\n         11. Any prior systemic chemotherapy within 5 years prior to inclusion for malignant\n             disease in the medical history\n\n         12. Any coexisting medical condition that in the opinion of the investigator could be a\n             risk in this study\n\n         13. Patient protected by law"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902680", 
            "org_study_id": "12 URO 06"
        }, 
        "intervention": {
            "arm_group_label": "Focal brachytherapy", 
            "description": "Focal brachytherapy with permanent I125 localized implant.", 
            "intervention_name": "Focal brachytherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Prostate cancer, permanent implant brachytherapy, image fusion, focal therapy, active surveillance", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "Bachaud.jean-marc@claudiusregaud.fr", 
                "last_name": "Jean-marc Bachaud, MD, PhD", 
                "phone": "+33 5.61.42.41.80", 
                "phone_ext": "4674"
            }, 
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France", 
                    "zip": "31052"
                }, 
                "name": "Institut Claudius REGAUD"
            }, 
            "investigator": [
                {
                    "last_name": "Jean-Marc BACHAUD, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Martine DELANNES, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sabrina BOYRIE, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.", 
        "overall_contact": {
            "email": "Bachaud.jean-marc@claudiusregaud.fr", 
            "last_name": "Jean-Marc Bachaud, doctor", 
            "phone": "+33 5.61.42.41.80", 
            "phone_ext": "4674"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Feasibility of focal therapy will be evaluated in terms of \"success\" or \"failure\" : success will be obtained in case of delivered dose of at least 152 Gy on the 1st dose enveloping the Planning Target Volume, evaluated on CT scan/MRI performed at Day 30", 
            "measure": "Feasibility of focal therapy will be evaluated with dosimetric study by CT scan / MRI performed 30 days after implantation", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free-survival is defined as the time from patient inclusion to the date of biological progression according to Phoenix criterion", 
                "measure": "Progression-free-survival according to Phoenix criterion", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Quality of life will be evaluated using 3 Patient questionnaires : the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ)C30 Questionnaire, the International Index of Erectile Function Questionnaire and the International Prostate Symptom Score Questionnaire", 
                "measure": "Quality of life study using 3 Patient questionnaires", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "The absence of tumor residuals in the target treated zone will be evaluated on on biopsies performed 1 year after implantation", 
                "measure": "Absence of tumor residuals in the target treated zone", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Toxicity will be evaluated according to the classification of NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0", 
                "measure": "Toxicity evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Institut Claudius Regaud", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Claudius Regaud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}